UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 9, 2020
Heat Biologics, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-35994
|
26-2844103
|
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
627 Davis Drive, Suite 400
Morrisville, North Carolina 27560
(Address of principal executive offices and zip code)
(919) 240-7133
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
|
|
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.0002 par value per share
|
HTBX
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
Emerging growth company ¨
|
|
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement
As previously announced, the Company’s subsidiary, Pelican Therapeutics, Inc. (“Pelican”), was awarded $15.2 million to fund preclinical and certain clinical activities from Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant”). The CPRIT Grant is subject to customary CPRIT funding conditions.
The CPRIT Grant initially covered a three-year period from June 1, 2017 through May 31, 2019. On April 12, 2019, CPRIT notified Pelican that it agreed to a six-month extension of time in order to conclude the approved scope of work, such that the completion date was extended from May 31, 2019 to November 30, 2019. On November 20, 2019, CPRIT notified Pelican that it agreed to a six-month extension of time in order to conclude the approved scope of work, such that the completion date was extended from November 30, 2019 to May 30, 2020. On April 9, 2020, CPRIT notified Pelican that it agreed to a six-month extension of time in order to conclude the approved scope of work, such that the completion date was extended from May 30, 2020 to November 30, 2020. All other terms and conditions of the CPRIT arrangement remained the same.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is filed with this Current Report on Form 8-K:
—————
*Confidential portions of this exhibit have been omitted from the exhibit.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
Dated: April 10, 2020
|
HEAT BIOLOGICS, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Jeffrey Wolf
|
|
|
Name:
|
Jeffrey Wolf
|
|
|
Title:
|
Chairman, President and
Chief Executive Officer
|
EXHIBIT INDEX
—————
*Confidential portions of this exhibit have been omitted from the exhibit.
EXHIBIT 10.1
PORTIONS HEREIN IDENTIFIED BY [*****] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
|
|
|
Grant ID: DP160012
|
PI/PD/CR: Jeff Hutchins
|
|
No Cost Extension with Attachment F
|
|
![[HTBX_EX10Z1001.JPG]](https://content.edgar-online.com/edgar_conv_img/2020/04/10/0001553350-20-000308_HTBX_EX10Z1001.JPG)
As indicated by the signatures below, the INSTITUTE and the RECIPIENT agree to the following amendments to the CPRIT Contract:
Original Contract End Date: 31 May 2019
Current Contract End Date: 30 May 2020
Proposed Contract End Date: 30 Nov 2020
Justification: [*****].
Contract Document F: Parties hereby agree that the RECIPIENT is granted a third six-month extension of time from the termination date reflected in the Attachment F-No Cost Extension (Version 2) approved on November 20, 2019, for purposes of concluding the approved scope of work as authorized by the Contract. Accordingly, the May 30, 2020 termination date is replaced with November 30, 2020. All terms and conditions of the Contract continue during the extension period. Parties agree that this extension is a “no-cost” extension and approval of this amendment does not approve, grant or confer additional grant funds in excess of the amount originally awarded.
Description: The May 30, 2020 termination date is replaced with November 30, 2020 for purposes of concluding the approved scope of work as authorized by the Contract.
|
|
|
|
|
|
RECIPIENT
Pelican Therapeutics
ASO Name: Jasuja, Rahul
Submitted Date: 02 Apr 2020
|
INSTITUTE
Cancer Prevention & Research Institute of Texas
CEO Name: Roberts, Wayne
Approved Date: 09 Apr 2020
|